Regenxbio Inc. v. Sarepta Therapeutics, Inc., No. 24-1408 (Fed. Cir. Feb. 20, 2026)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

REGENXBIO Inc. and The Trustees of the University of Pennsylvania (collectively, “ REGENXBIO”) filed a pa- tent infringement suit in the U nited States District Court for the District of Delaware against Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC for infringing claims 1–9, 12, 15, and 18–25 of U.S. Patent No. 10,526,617. Both parties moved for summary judg- ment of patent eligibility under 35 U.S.C. § 101. The dis- trict court granted Sarepta’s motion and held the claims ineligible under § 101 as directed to a natural phenome- non.